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Abstract
Background: Excessive maturation of hematopoietic cells leads to a reduction of long-term
proliferative capability during cord blood (CB) expansion. In this study, we report the effects of
anit-CD52 (Alemtuzumab, Campath) on both short- and long-term ex vivo expansion of CB
hematopoietic stem cells (HSC) by evaluating the potential role of Alemtuzumab in preserving the
repopulating capability in CB HSC and nonlymphoid progenitors.
Methods: Ex vivo expansion experiments were carried out using freshly purified CB CD34+ cells
in StemSpan™ SFEM medium in the presence of stem cell factor, Flt3-Ligand and thrombopoietin
at 50 ng/ml. Alemtuzumab (10 μg/ml) was used to deplete CD52+ cells during the cultures. Flow
cytometry was used to monitor CB HSC and their differentiation. Colony forming unit (CFU)
assays and long term culture-initiating cell (LTC-IC) assays were performed on cells obtained from
day 0 (before culture) and day 14 after cultures. Secondary cultures was performed using CD34+
cells isolated at 35 days from primary cultures and further cultured in StemSpan™ SFEM medium
for another 14 days to confirm the long term effect of alemtuzumab in liquid cultures.
Results: Compared to cytokines alone, addition of alemtuzumab resulted in a significant increase
in total nucleated cells, absolute CD34+ cells, myeloid and megakaryocytic progenitors, multi-
lineage and myeloid CFU and LTC-IC.
Conclusion: The results from current study suggested that the use of alemtuzumab for ex vivo
expansion of CBHSC maybe advantageous. Our findings may improve current technologies for
CBHSC expansion and increase the availability of CB units for transplantation. However, in vivo
studies using animal models are likely needed in further studies to test the hematopoietic effects
using such expanded CB products.
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Background
Umbilical cord blood transplantation (CBT) is now an
established means of hematopoietic stem cell (HSC)
transplantation for patients with a variety of malignant
and non-malignant disorders [1-3]. As the results of par-
tially matched CBT are similar to those of fully matched
unrelated bone marrow transplantation, there has been a
significant increase in CBT for patients in need of trans-
plantation with matched unrelated allogeneic HSC. This,
coupled with the immediate availability of cord blood
units (CBU), has made cord blood an ideal source for
pediatric HSC transplantation [4-8].
Due to the low number of HSC in each CBU, double unit
CBT has been attempted and the results show that the two
CBU have an additive effect, resulting in engraftment
times equivalent to a single unit CBU with the cumulative
cell dose of both the units [9-12]. However, while this
treatment modality has increased cord blood usage in
adult patients, many patients remain ineligible, as the
total cell dose of two CBU may still be insufficient for
many adult patients. In recent years, ex vivo expansion of
HSC has been used as another approach for obtaining suf-
ficient CBHSC from a single CBU in order to obtain ade-
quate repopulating HSC from a single CBU. However,
despite considerable research, ex vivo expansion of CB
HSC has not definitively resulted in improved clinical
outcomes in CBT [13-15], and failure or delayed hemat-
opoietic engraftment was encountered in some earlier
attempts using ex vivo expanded CB products, despite of
satisfactory and impressive results from preclinical ex vivo
experiments [16-18]. Stiff and colleagues have success-
fully transplanted patients with small aliquots of autolo-
gous bone marrow (BM, median volume = 36.7 ml with
lowest volume = 13 ml) in Aastrom/Replicell stromal-
bases close system in serum-containing medium using
GM-SCF-IL-3 fusion protein, Flt3-L and erythropoietin as
sole-source of HSC in 19 patients with breast cancer.
Long-term hematopoietic reconstitution was achieved
without an increase in infection or late graft failure for up
to 8 years [14,19]. Rice and colleagues reported that the
response to short-term cytokine exposure in different CB
hematopoietic cell populations was mainly from the
mature cell populations rather than from the stem cell
population [20]. Their observation at least partially
explained the pitfalls in clinical-scale transplantation
using ex vivo CB products. To overcome this problem, new
approaches for ex vivo expansion need to be developed,
aiming at expansion of the "stem" cell population in cord
blood and improving the long-term hematopoietic recon-
stitution in cord blood transplantation [14,21].
CD52 is a phosphatidylinositol-linked, 12-amino acid
leukocyte differentiation antigen abundantly expressed
on the surface of activated lymphocytes, monocytes, mac-
rophages, monocyte-derived dendritic cells and endothe-
lial cells [22-25]. Alemtuzumab, a humanized anti-CD52
monoclonal antibody, was approved by FDA in 2001 for
the clinical administration in patients with chronic lym-
phoblastic leukemia (CLL). Alemtuzumab results in rapid
clearance of CD52+ cells by complement-mediated target
cell lysis and antibody mediated cellular toxicity [26,27].
Alemtuzumab is now commonly used for the treatment of
lymphoid malignancy, such as chronic lymphoid leuke-
mia (CLL) [28]. Previous publications show that alemtu-
zumab could also enhance megakaryopoiesis [22,29].
Based on these earlier observations, we postulated that
depletion of CD52+ cells with alemtuzumab in ex vivo
expansion experiments of CBU may lead to a higher per-
centage of CD34+ cells through depletion of more mature
CD52+ hematopoietic progenitors. Hence, we embarked
on this study to evaluate the potential role of Alemtuzu-
mab in preserving primitive CB HSC during ex vivo cord
blood expansion.
Results
Evaluation of the quality of CB CD34+ hematopoietic 
progenitors and stem cells
The purity of CD34+ cells after immunomagnetic separa-
tion was 85.72 ± 5.98% (n = 6). The result was confirmed
by Aldeflour staining (Figure 1); 81.05% cells were both
CD34+  and Bodipy-aminoacetate (BAAA) brightly
stained, 12.65% CD34+cells did not express BAAA activ-
ity. In total, there were 86.50% cells brightly expressing
BAAA in CD34-enriched cell population. The data are
consistent with previous reports [30-32] and provides sec-
ondary confirmation of the cell selection efficiency and
that primitive and naïve hematopoietic progenitors were
present within our initiating cells.
Effect of alemtuzumab on total nucleated cells (TNCs) and 
CB CD34+ cells
As shown in Figure 2A, TNCs were expanded 20.90 ± 2.89
fold on day 14 with alemtuzumab, which was 1.36-fold
more than control (15.33 ± 2.45, p < 0.05). The absolute
CD34+ cell count (Figure 2B) was 3.06 × 105 ± 0.58 × 105,
in cultures with alemtuzumab, compared to control (1.93
× 105 ± 0.31 × 105. Compared to control cultures, the
absolute CD34+ cell numbers were 58.55% higher with
alemtuzumab added in the cultures (N = 6, p < 0.05).
Effect of alemtuzumab on lymphoid, megakaryocytic and 
myeloid cells
As shown on Table 1, the addition of alemtuzumab
resulted in a 98.48% reduction in the proportion of abso-
lute CD52+ cells (0.02 × 105 ± 0.02 × 105 versus 1.32 × 105
± 0.44 × 105 in controls; N = 6 p < 0.05) and 96.36%
reduction in the proportion of CD90+ lymphoid progeni-
tors (0.02 × 105 ± 0.01 × 105 versus 0.55 × 105 ± 0.24 × 105
in controls; N = 6 p < 0.05). Mature lymphocyte markers,Journal of Hematology & Oncology 2008, 1:19 http://www.jhoonline.org/content/1/1/19
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such as CD3 and CD19 were also tested, but as the current
cytokine combination did not favor lymphoid cell prolif-
eration, the percentage was too low (<0.3%) to demon-
strate any potential effects on the addition of
alemtuzumab. On the other hand, in the presence of ale-
mtuzumab, more expansion of CD13+ myeloid progeni-
tors (44.35%) was observed compared to controls. The
expression of glycophorin A appeared to be marginally
enhanced by alemtuzumab, but the difference was not sta-
tistically significant.
Effect of alemtuzumab on megakaryocytes
As shown in Figure 3A, there was 28.75% greater expan-
sion of CD41+ megakaryocytes in the presence of alemtu-
zumab on day 7 cultures (1.03 × 105 ± 0.39 × 105 with
alemtuzumab vs 0.80 × 105 ± 0.23 × 105 without; N = 6, p
CD34 selection efficiency by aldefluor assay and flow-cytometry assay Figure 1
CD34 selection efficiency by aldefluor assay and flow-cytometry assay. After CD34 selection, cells were stained with 
CD34-PE and Aldefluor. CD34+ stem cells were selected according to forward scatter (FSC) and side scatter (SSC) properties 
using the gated region R1 to remove cell debris, residual platelet and red cell contamination. Figures were representative of 6 
separate experiments. A: Phenotype of day 0 CD34+ selected cells that initiate the culture. The percentages of cells positive for 
the CD34-PE and Bodipy-aminoacetate (BAAA) were obtained from gates R1. B: Isotype expression pattern for IgG-PE and 
BAAA. C: Expression profile of stem cells co-staining with CD34-PE and BAAA. As shown in the Fig, based on R1 gating, 
81.05% cells were both CD34 positive and BAAA brightly stained, 12.65% cells were CD34 positive but BAAA negative. 
86.50% of the CD34+ cells were brightly stained with BAAA.Journal of Hematology & Oncology 2008, 1:19 http://www.jhoonline.org/content/1/1/19
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< 0.05) and 55.59% greater expansion on day 14 cultures
(4.73 × 105 ± 0.71 × 105 with alemtuzumab vs 3.04 × 105
± 0.52 × 105 without; N = 6, p < 0.05). These observations
are consistent with previous reports, which show that Ale-
mtuzumab enhances megakaryopoiesis [22,29].
Colony Forming Unit (CFU) assay
CFU-GEMM and CFU-GM were significantly improved
with 14 days of alemtuzumab expansion culture. As
shown in Figure 4A, CFU-GEMM was expanded 2.05 ±
0.42 fold with alemtuzumab compared to 1.48 ± 0.29
fold in control (p < 0.05). CFU-GM was expanded 1.70 ±
0.04 and 1.27 ± 0.07 fold with or without alemtuzumab
treatment respectively. Erythroid colonies (BFU-E/CFU-E)
Effects of alemtuzumab on total nucleated cells and CD34+ cells Figure 2
Effects of alemtuzumab on total nucleated cells and CD34+ cells. 100,000 CD34+ cells were cultured in 2 ml Stem-
Span™ SFEM Medium supplemented with 10% of healthy human serum, 50 ng/ml of stem cell factor, TPO and Flt3 Ligand. 10 
μg/ml of alemtuzumab was added to test the alemtuzumab's effects on HSC expansion. Cultures were maintained at 37°C with 
humidified air containing 5% CO2 for 5 weeks. A small fraction of the cultures were harvested at day 7, 14 to test absolute 
total nucleated cell expansion. (A), CD34+ cell percentages (B), Absolute CD34+ cell numbers in control and alemtuzumab 
treatment groups. Results are representative of 6 separate experiments from different fresh cord blood samples.
Table 1: Effects of alemtuzumab on lineage differentiation during ex vivo expansion of CB stem cells
Cell Surface Markers Expression Level
Control Cultures Cultures with alemtuzumab
Percentage ± SD Absolute Cell Count (× 105) Percentage ± SD Absolute Cell Count (× 105)
CD52 8.63 ± 2.49 1.32 ± 0.44 0.10 ± 0.08 0.02 ± 0.02
CD90 3.58 ± 1.46 0.55 ± 0.24 0.10 ± 0.03 0.02 ± 0.01
CD14 23.01 ± 3.73 3.53 ± 0.80 17.71 ± 3.18 3.70 ± 0.84
Glycophorin-A 0.57 ± 0.33 0.09 ± 0.05 0.71 ± 0.48 0.15 ± 0.10
CD13 84.86 ± 4.27 13.01 ± 2.18 89.85 ± 1.88 18.78 ± 2.63
CD41 19.82 ± 1.12 3.04 ± 0.52 22.63 ± 1.32 4.73 ± 0.71
Phenotype of day-14 ex vivo expansion cultures: Liquid cultures for 14 day ex vivo expansion were established with 100,000 CD34+ cells in 
50 ng/ml of SCF, TPO and Flt-3 Ligand. The results of six separate experiments are expressed in terms of different surface marker expression levels 
on day 14.Journal of Hematology & Oncology 2008, 1:19 http://www.jhoonline.org/content/1/1/19
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were nearly 2-fold decreased compared to initial cells in
both conditions (0.4 ± 0.17 vs. 0.54 ± 0.18 fold expansion
with or without alemtuzumab, respectively), which par-
tially offset the total CFU (CFU-GM + BFU-E/CFU-E +
CFU-GEMM) expansion (1.45 ± 0.23-fold in alemtuzu-
mab treatment groups, p < 0.05 vs. 1.11 ± 0.16 in control,
p < 0.05, compared to initiate cells). To further demon-
strate the effect of alemtuzumab on expansion, relative
CFU expansion fold was calculated (Fig 3B). Expansion
cultures carried out in the presence of alemtuzumab
resulted in 1.40 ± 0.06, 1.34 ± 0.04 and 1.31 ± 0.04 fold
more expansion in CFU-GEMM, CFU-GM and total CFU
respectively (p < 0.05).
Effect of alemtuzumab on megakaryocytes Figure 3
Effect of alemtuzumab on megakaryocytes. Cells were cultured in the same condition as described in Fig 2 and har-
vested at Day 7 and Day 14 for analysis. A: Absolute CD41+ cell numbers. B: Relative CD41+ cell expansion with Alemtuzumab 
versus control. (N = 6, p < 0.05).
CFU and LTC- IC expansion fold under different culture conditions Figure 4
CFU and LTC- IC expansion fold under different culture conditions. A: CFU expansion fold under different culture 
conditions: After 14 days culture, cells were harvested from different culture conditions and put to Methocult H4435 medium 
for another 2 weeks. CFU-GM, BFU-E/CFU-E and CFU-GEMM were counted according to their morphologic characters. 
Comparison of absolute CFU (total CFU together with three different types of CFU) expansion fold after 14 days culture with 
or without alemtuzumab treatment is shown. The results of three separate experiments performed in duplicate are expressed 
in term of the CFU expansion fold on day 14 compared to day 0 initiating cells. B: LTC-IC expansion fold under different cul-
ture conditions: LTC-IC was performed on cells before and after 14 days of culture and, in the absence or presence of alemtu-
zumab. Results are from 3 separate experiments from performed in triplicate on separate fresh cord blood samples.Journal of Hematology & Oncology 2008, 1:19 http://www.jhoonline.org/content/1/1/19
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Long-term culture-initiating cell (LTC-IC) assay
LTC-IC was performed on cells before and after 14 days of
culture and, in the absence of alemtuzumab, there was a
53% ~75% decrease in LTC-IC compared to initial CD34+
cells (prior to culture). In the presence of alemtuzumab,
LTC-IC was sustained at 1.17 ± 0.20 compared to the ini-
tial cells (Figure 4B). Thus, addition of alemtuzumab into
the cultures resulted in 1.45- to 2.25- (mean 1.95 ± 0.44)
fold greater numbers of LTC-IC compared to controls (p <
0.05).
Secondary cultures of CD34+ cells
Secondary cultures was performed using CD34+ cell iso-
lated from day 35 of ex vivo expansion cultures to confirm
the long-term growth of CD34+ cell in liquid cultures. The
purity of CD34+ cells was 85.00%, similar to that observed
with fresh CB CD34+ cell isolation. The CD34+ cells were
further cultured for up to two weeks (49 days) with iden-
tical combinations of cytokines with alemtuzumab 10 μg/
ml. Secondary cultures without alemtuzumab were used
as controls. A significantly higher percentage of CD34+
cells (10.96 ± 5.09% vs. 2.24 ± 0.53%) was observed at
day 42 (p < 0.05) and day 49 (2.34 ± 1.14% vs. 0.57 ±
0.39%, p < 0.05, Figure 5), respectively. At day 42, CD52+
cell population was 0.53 ± 0.31% with alemtuzumab vs.
5.59 ± 0.79% without alemtuzumab) and at day 49,
CD52+ cells were 0.93 ± 0.55% with alemtuzumab vs.
16.56 ± 2.28% without alemtuzumab. Even at day 42 of
culture, absolute CD34+ cells in cultures with alemtuzu-
mab showed a 15% increase while the cultures without
alemtuzumab showed a 76% decrease (absolute CD34+
expansion fold: 0.24, Figure 5B). By day 49, both cultures
conditions showed a net loss of CD34+ cell numbers
(absolute CD34+ numbers as percentage of original: 8%
of original in control cultures vs 36% of original with ale-
mtuzumab, Figure 5B).
Discussion
The results from this study showed that the anti-CD52
antibody Alemtuzumab significantly enhanced ex vivo
expansion of CB CD34+ cells and TNC. In addition, com-
pared to both the initiating cells and cytokines-alone con-
trol cultures, total CFU, especially CFU-GEMM and CFU-
GM were expanded after treatment of alemtuzumab, and
LTC-IC numbers preserved, confirming the retention of
hematopoietic progenitors. Furthermore, the effects of
alemtuzumab were more pronounced when the culture
was extended for 49 days (14 days secondary cultures
taken from CD34+ cells selected out at day 35 of primary
cultures). Although there is a net loss of CD34+ cell at day
49, the alemtuzumab did preserve more CD34+ cells
compared to control cultures, which had loss of almost all
Alemtuzumab long-term efforts on CD34+ cells secondary culture Figure 5
Alemtuzumab long-term efforts on CD34+ cells secondary culture. CD34+ cells were isolated from day 35 cultures 
and put into secondary culture with the original cytokine combination (50 ug/ml SCF, TPO and Flt-3 Ligand) and 10% human 
serum, with or without 10 μg/ml alemtuzumab (control group). After a further 7 to 14 days of culture, cells were harvested to 
analyze CD34 and CD52 expression profiles. A: Expression profiles of CD34 and CD52 at Day 7 and Day 14 of secondary cul-
tures. B: Absolute expansion fold of CD34+ cells of secondary cultures. The absolute expansion fold is calculated by the abso-
lute CD34+ cells number as compare to secondary culture initiate CD34+ numbers. The results are from three separate 
experiments.Journal of Hematology & Oncology 2008, 1:19 http://www.jhoonline.org/content/1/1/19
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CD34+ cells by day 49. This is likely because of the fact
that differences in preserving progenitor/primitive cell
populations become more prominent with longer term
cultures, further confirming that alemtuzumab could
potentially preserve primitive CD34+ hematopoietic cells.
Although the degree of expansion was modest, our exper-
iments were aimed at comparing expansion with/without
alemtuzumab, and were reasonable for this "early phase"
cytokine combination, which was targeted at retaining
immature stem cell populations rather than an over-
whelming increase in absolute cell numbers. Immuno-
homeostasis in in vivo transplantation/engraftment are far
more complicated that just an ex vivo study and the results
of ex vivo expansion caused by addition of alemtuzumab
this study was indirect. As there was depletion of CD52
cells associated with the addition of alemtuzumab, future
experiments will see if adding back CD52+ cells would
abrogate the effect of alemtuzumab. Further optimization
with the use of this drug in other cytokine combinations
in large-scale expansion cultures is being carried out,
including the SCID-repopulating assay.
One important issue in HSC expansion has always been
the concern that expanding mature cell populations at the
expense of the primitive progenitors could affect durable
engraftment capacity [33]. The underlying mechanisms
for alemtuzumab enhancement of in vitro cord blood
expansion could be secondary to selective depletion of
CD52+ populations, such as lymphocytes and monocytes.
Moreover, depletion of CD52+ cell populations may result
in removal of certain inhibitory cell populations, such as
CD26+ lymphocytes and NK cells during ex vivo expan-
sion of CB HSC [20,34]. The ability to retain the hemat-
opoietic progenitors and stem cells in culture would
enhance the likelihood of stable engraftment in recipients
of these expanded products. Another potential risk of HSC
expansion is the mature lymphocytes arising from these
cultures, which could lead to a higher incidence of graft
versus host disease (GVHD), thus negating a major bene-
fit of CBT – which is the lowered incidence and severity of
GVHD with increased tolerance towards HLA mismatches
[3,35-37]. In our study, mature cells and lymphocytes
were actively removed in culture with the maintenance of
hematopoietic progenitors and stem cells, and a relative
expansion of myeloid and megakaryocytic precursors;
thus appearing to circumvent these two theoretical risks of
expansion. Moreover, a recent study from Shah et al
shows that alemtuzumab is effective in decreasing the
incidence of GVHD without increasing the risk of relapse
in pediatric patients [38]. Despite an initial proportional
decrease in lymphocytes/monocytes, there was no subse-
quently absolute decrease of CD13+, CD14+ and CD15+
cell numbers, after 14 days of culture. Many clinical cord
blood expansion trials now incorporate the expansion of
one unit of cord blood following the infusion of another
unexpanded unit in a double cord blood transplant set-
ting. The unexpanded unit has, thus served successfully as
a backup for potential loss of engraftment potential after
cord blood expansion while the expanded unit serves to
provide the first wave of myeloid recovery, thus decreas-
ing the long engraftment period of CBT [39].
Conclusion
In summary, our study shows that the use of alemtuzu-
mab in ex vivo cord blood expansion results in an increase
in total cell expansion while preserving hematopoietic
CD34+ cell content. Furthermore, the expansion of mye-
loid and megakaryocytic precursors is also enhanced. This
finding may contribute to current technologies in CB
expansion and increase the availability of CBT for patients
around the world.
Methods
Sample collection
CB samples were obtained from the Singapore Cord
Blood Bank (SCBB) that failed to meet the banking crite-
ria for storage. This study was approved by the Hospital's
Ethics Committee. Further allocation of CBU used for this
study was re-confirmed by the SCBB Research Advisory
Ethics Committee. A total of nine CBU were used in this
study. Three for CFU and LTC-IC study while six for the ex
vivo expansion and flow analysis.
CB CD34+ cell isolation
Cord blood CD34+ cells were isolated prior to expansion
using a magnetic-cell sorting device (VarioMACS,
Miltenyi, Germany). Briefly, mononuclear cells were frac-
tionated by Ficoll-HypaquePlus  (Amersham Pharmacia
Biotech, Upsala, Sweden) density centrifugation. The
CD34+ cell fraction was then isolated using the direct
CD34 isolation kit, LS columns and VarioMACS magnetic
cell separator (Miltenyi Biotec, Germany) according to the
manufacturer's instructions. The purity of the selected
population was verified with anti-human CD34+ antibody
conjugated with phycoerythrin (PE, Anti-HPCA-1, Becton
Dickinson, San Jose, USA) and analysed using the FACS-
Calibur flow cytometer and CellQuest Pro software (Bec-
ton Dickinson). Aldefluor assay was used to evaluate the
activity of aldehyde dehydrogenase in the sorted CB
CD34+ cells using the reagents from Stem Cell Technol-
ogy (Stem Cell Technology, Vancouver, Canada) and the
FACSCalibur flow cytometric analysis [30,32,40].
Ex vivo expansion cultures of cord blood CD34+ cells
105 CD34+ cells isolated from same CBU were cultured in
2 ml StemSpan™ SFEM Medium (10%BSA, 10 μg/ml
recombinant human insulin, 200 μg/ml human transfer-
rin, 104M 2-mercaptoethanol and 2 mM L-glutamine in
Iscove's MDM, StemCell Technologies, Vancouver, Can-Journal of Hematology & Oncology 2008, 1:19 http://www.jhoonline.org/content/1/1/19
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ada) supplemented with 50 ng/ml of stem cell factor
(SCF, from Chemicon, USA), 50 ng/ml of thrombopoie-
tin (TPO, from Chemicon, USA), 50 ng/ml of Flt-3 Ligand
(Chemicon, USA), and 25 ng/ml of penicillin (10,000
uits/ml) and streptomycin (40 mg/ml, Gibco, USA). 10
μg/ml of alemtuzumab (Schering AG, Germany) was
added with 10% of healthy human serum (collected from
a consistent healthy adult donor with Ethics Committee
approval) as a source of human complement. All cultures
were performed at 37°C with humidified air containing
5% CO2. Culture medium was replenished on day 4, 7,
10, 14 with simultaneous harvest of small aliquots of cells
for counts, phenotypic analysis, and culture assays.
Trypan blue exclusion was used to determine cell viability.
A total of six experiments were performed from six differ-
ent CBU.
Flow cytometry analysis
The effect of alemtuzumab on CD34+ stem cells popula-
tions after ex-vivo expansion of cord blood HSC was ana-
lyzed by flow cytometric analysis using a panel of
monoclonal antibodies (mAbs), including CD34 and lin-
eage specific mAbs against myeloid, erythroid, megakary-
ocytic and lymphoid lineages (CD13, CD14, CD90, CD41
and Glycophorin A, from Becton Dickinson, San Jose,
USA and CD52, from Serotec, USA). Samples were incu-
bated with mAbs at 4°C for 30 min, washed, fixed,
acquired and analyzed using a FACSCalibur flow cytome-
ter. At least 10,000 events were acquired for each analysis.
Colony Forming Unit (CFU) assay
Colony assay was performed triplicate on cells obtained
from day 0 (before culture) and day 14 after cultures. Cells
were plated on 35 mm petri dishes (Nunc, Denmark) after
mixing well with Methocult H4435 medium (1% methyl-
cellulose in Iscove's MDM, 30% fetal bovine serum, 1%
bovine serum albumin, 104 M 2-mercaptoethanol, 2 mM
L-glutamine, 50 ng/ml SCF, 20 ng/ml, GM-CSF, 20 ng/ml
IL-3, 20 ng/ml IL-6, 20 ng/ml G-CSF and 3 U/ml EPO,
from Stem Cell Technologies, Vancouver, Canada). After
incubation for 14 days at 37°C, granulocyte and macro-
phage colony forming units (CFU-GM), burst forming
unit erythroid/erythroid colony forming units (BFU-E/
CFU-E) and granulocyte-erythroid-macrophage-meg-
akaryocyte colony forming units (CFU-GEMM) were enu-
merated according to manufacturer's guidelines under an
inverted microscope (Axiovert 25, Carl Zeiss Pte Ltd, Sin-
gapore).
Quantitative bulk culture assay of long-term culture-
initiating cell (LTC-IC)
Bulk culture LTC-IC assay was established and maintained
in triplicate following manufacturer's instructions (Stem
Cell Technologies, Vancouver, Canada). Briefly, stromal
layers were initiated with M2-10B4 murine fibroblast cell
line (CRL1972) by seeding 1 × 106 cells in a 75 cm2 culture
flask in 15 ml RPMI (Gibco, Grand Island, NY, U.S.A)
with 10% fetal calf serum (Hyclone, Logan, UT, USA).
Half of the medium was changed weekly, and at log-phase
growth, cells were trypsinized (Trypsin-EDTA; Invitrogen,
U.S.A) and irradiated with an adsorbed dose of 8,000 cGy
with a 60Co gamma irradiator (J.L. Shepherd & Associates,
Canada). Feeder layers were then cultured in Long-term
Culture Medium H5100 (12.5% horse serum, 12.5% FBS,
0.2 mM inositol, 20 mM folic acid, 104M 2-mercaptoeth-
anol, 2 mM L-glutamine in MEM- medium, from Stem
Cell Technologies, Vancouver, Canada) supplemented
with 106mol/L hydrocortisone 21-hemisuccinate (Stem
Cell Technologies, Vancouver, Canada). 24 hours later,
freshly isolated day 0 CD34+ cells and day 14 expanded
cells were added in triplicates to irradiated M2-10B4 stro-
mal layer. Cultures were maintained at 37°C 5% CO2 and
100% humidity for 5 weeks with 50% volume of medium
changed weekly. At the end of the 5th week, all the cells
were harvested together (non-adherent cells were pipetted
off and adherent cells were trypsinized) and fractions of
cells were plated for CFU assay in H4435 medium as
described above. After incubation for another 14 days at
37°C, total CFU numbers were counted and normalized
against the initial cells. LTC-IC expansion was calculated
from the LTC-IC derived total CFU numbers before and
after culture under different conditions.
Secondary culture for day 35 CD34+ cells
To study the long term effects of alemtuzumab on hemat-
opoietic progenitors and stem cells, cells were cultured for
up to 35 days and CD34+ cells were isolated using MACS
from day 35 cultures with alemtuzumab as described
above. The purity of CD34+ cells was tested by flow cytom-
etry analysis and selected CD34+ cells were put into sec-
ondary culture with the same cytokine combination and
10% human serum, with or without 10 μg/ml alemtuzu-
mab. After a further 7 to 14 days of culture, cells were har-
vested and analysis of CD34 and CD52 expression
profiles was performed.
Statistical analysis
Data was shown as mean ± SD. Group comparison for the
statistical significance was calculated using Wilcoxon
matched pairs nonparametric test. A p value of less than
0.05 was considered to be statistically significant.
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